Quick Facts

• Primary Use: Treatment of Exocrine Pancreatic Insufficiency (EPI).
• Associated Conditions: Cystic fibrosis, chronic pancreatitis, pancreatectomy, and other medically defined pancreatic diseases.
• Therapeutic Benefit: Supports the digestion and absorption of fats, proteins, and carbohydrates from food.

---

Cotazym is a prescription medication utilized in the treatment of Exocrine Pancreatic Insufficiency (EPI) in both adult and pediatric patients. This condition occurs when the pancreas is unable to produce or release sufficient digestive enzymes needed to break down food normally.

This medication is indicated for EPI that is attributed to underlying medical issues, including:

• Cystic fibrosis (CF)
• Chronic pancreatitis (long-term swelling of the pancreas)
• Pancreatectomy (surgical removal of part or all of the pancreas)

By helping the body process fats, proteins, and starches from ingested food, Cotazym provides a replacement for missing natural enzymes. The key therapeutic benefit is to promote adequate nutrient absorption and to help manage symptoms of malabsorption, such as fatty bowel movements and nutritional deficits. The necessity for pancreatic enzyme replacement therapy (PERT) should be determined by a healthcare provider.

---

Regulatory References

1. NIH MedlinePlus guidance on pancrelipase

Cotazym's official eligibility is defined by regulatory guidelines, outlining which populations are approved for use and which are explicitly restricted or contraindicated.

Eligibility Scope	Status/Restriction
Approved Populations	Adults and pediatric patients (including infants) with Exocrine Pancreatic Insufficiency (EPI).
Contraindicated Groups	Patients with known hypersensitivity to porcine protein or any component of the formulation.
Condition Restriction	Use is prohibited during acute pancreatitis or an acute exacerbation of chronic pancreatitis.

Condition-Specific Use

Caution is officially advised for use in patients with pre-existing conditions that affect uric acid levels, such as gout or renal impairment (kidney disease). High-dose use in pediatric patients with cystic fibrosis carries a warning related to fibrosing colonopathy.

Pregnancy and Lactation

Use during pregnancy is generally restricted unless the clinical benefits are determined to outweigh potential risks. For nursing mothers, caution is advised as it is unknown if the product's components are excreted in breast milk.

Cotazym (Pancrelipase) is an enzyme replacement therapy that acts locally within the gastrointestinal tract and is not absorbed into the bloodstream. This pharmacological profile dictates the nature of its interaction patterns, leading to the official regulatory classification that systemic pharmacokinetic interactions, such as those involving CYP liver enzymes or drug transporters, are not expected or officially documented.

The documented interaction profile focuses on local effects, primarily involving the absorption or efficacy of other orally administered products. Two main categories of interaction are recognized.

First, co-administration may reduce the effectiveness of certain medicines designed to manage digestion or nutrient breakdown. For example, Pancrelipase may reduce the efficacy of alpha-glucosidase inhibitors (such as Acarbose) due to a functional interference where the administered enzymes counteract the inhibitor's action. Second, the administration of Pancrelipase may interfere with the absorption of specific supplements. Regulatory information states that Pancrelipase may reduce the absorption and systemic exposure of both iron supplements and folic acid supplements. To mitigate this absorption interference, official labeling advises that the administration of Pancrelipase and these supplements should be separated by time. Additionally, certain antacids containing calcium or magnesium may reduce the overall efficacy of the Pancrelipase product itself.

Cotazym is an exogenous mixture of digestive enzymes delivered to the gastrointestinal tract. Upon transit through the stomach, the formulation is designed to release its active components—lipase, protease, and amylase—into the lumen of the small intestine.

Lipase catalyzes the hydrolysis of dietary triglycerides into monoglycerides and free fatty acids. Protease facilitates the cleavage of peptide bonds within proteins, yielding smaller peptides and amino acids. Amylase modulates the breakdown of starch and complex carbohydrates into simple sugars.

This concurrent enzymatic activity at the absorptive surface facilitates the intraluminal digestion of macronutrients. The resulting smaller, soluble molecules are then available for absorption across the intestinal epithelium, modulating the systemic availability of these assimilated nutrients. The mechanism is a pure replacement of endogenous catalytic activity required for complete nutrient processing.

How to use Cotazym (Pancrelipase)

Cotazym is an oral medication taken to help break down and absorb nutrients from food. The following describes the administration of the product.

---

Administration Protocol

Route of Administration: Oral.

Dosing and Frequency: The dose is determined by a doctor based on the patient's individual needs, the severity of the disease, and the diet, including the amount of fat consumed. Patients are typically directed to take the prescribed number of capsules with each meal and snack. Do not take more capsules in a day than the maximum daily dose established by a healthcare provider.

Timing in relation to meals: Cotazym must be taken with a meal or snack to ensure the enzymes are present in the digestive tract at the appropriate time.

Preparation Steps:

• Swallow the capsule(s) whole with a sufficient amount of liquid (such as water or juice).
• Do not crush or chew the capsules or their contents, as this can cause irritation in the mouth and affect the medication's effectiveness.
• For those unable to swallow the capsule whole: The capsule may be opened, and the contents (microspheres) can be sprinkled onto a small amount of soft, acidic food (e.g., applesauce, yogurt). The mixture must be swallowed immediately without chewing, followed by a drink of water or juice.

Missed Dose: If a dose is missed, skip the missed dose and continue with the next scheduled dose. Do not take a double dose to make up for the missed one.

---

Summary of Use Constraints: Administration requires adherence to the individualized dosing schedule, the procedural mandate of swallowing the intact capsule or unchewed contents, and the timing of administration in conjunction with food. This ensures the controlled release of the pancreatic enzymes within the small intestine.

Research Evidence / Overview of Studies for Cotazym (Pancrelipase)

---

Evidence for Use in Exocrine Pancreatic Insufficiency (EPI) due to Cystic Fibrosis

The use of Pancrelipase for Exocrine Pancreatic Insufficiency (EPI) in individuals with Cystic Fibrosis (CF) was evaluated in clinical research studies. The evidence base includes short-term Randomized Controlled Trials (RCTs) and also involves longer-term observational studies. These trials were primarily focused on research examining objective digestive function markers.

Research examined the objective variables related to fat breakdown in study participants. The main objective outcome studied for was the Coefficient of Fat Absorption (CFA), a variable measured in research on nutrient absorption. The research was studied for in study populations ranging from infants and children (pediatric patients) through adults with confirmed CF-related EPI. Short-term trials reported data that show patterns related to the measured CFA over the study period when compared to a placebo (an inactive treatment).

---

Evidence for Use in Exocrine Pancreatic Insufficiency (EPI) due to Chronic Pancreatitis or Pancreatectomy

For individuals whose EPI results from chronic pancreatitis or surgical removal of the pancreas (pancreatectomy), research also primarily relies on short-term, placebo-controlled RCTs. These studies were evaluated in adult patient populations presenting with EPI. The research studied the objective variables related to digestion in these adults, using the Coefficient of Fat Absorption (CFA) as the core measure.

Studies conducted during defined intervals reported measurements of CFA. Research monitored changes measured during the study period concerning symptomatic outcomes, though results were mixed across studies. The evidence derived from these settings focuses on short-term changes, and the findings describe group patterns; research provides context but not individual predictions.

---

Key Evidence Gaps and Areas of Uncertainty

Long-term outcomes are not fully established in controlled trials, as the most rigorous evidence comes from studies with limited follow-up durations, typically lasting only one to two weeks. Data for certain groups remain insufficient, especially for specific populations with coexisting conditions. Research is ongoing to provide further insight into the short-term changes and objective variables studied for individuals with chronic EPI.

Common questions about Cotazym (FAQ)

---

Q: What is the main difference between Cotazym and other pancreatic enzyme products?

Cotazym is one specific brand of Pancrelipase, which is a combination of three digestive enzymes. Official product information for Cotazym, like the ECS 8 and ECS 20 variants, defines it by its specific unit strengths of lipase, amylase, and protease per capsule. These exact strengths and the physical form (delayed-release, enteric-coated microspheres) often vary between different pancrelipase brands.

---

Q: Does Cotazym help with all types of digestion issues, or is it only for specific conditions?

Official labeling and studies indicate that Cotazym is specifically designed and indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI). This is a condition where the pancreas does not make enough enzymes to properly digest food. The drug's therapeutic use is therefore focused on EPI resulting from conditions like cystic fibrosis or chronic pancreatitis.

---

Q: Does taking Cotazym require any regular blood work or monitoring?

As a prescription medication, all pancrelipase products, including Cotazym, require continuous supervision by a healthcare professional. According to regulatory guidelines, monitoring is necessary to support the safe and effective use of the drug. This monitoring helps assess the patient's response and support appropriate management of the condition.

---

Q: Can Cotazym be taken with hot liquids or foods?

The enzymes within the capsule are sensitive to heat, and high temperatures may cause them to become deactivated, reducing the effectiveness of the medication. Official guidance indicates that swallowing the capsules with cold or room temperature liquids is generally advised.

---

Q: Does Cotazym interact with alcohol or tobacco?

Official labeling indicates that the use of alcohol or tobacco may be a factor in the proper use of this medicine. Patients should discuss the use of alcohol or tobacco with their healthcare professional to ensure appropriate management while using the drug.

---

Q: Are there risks associated with inhaling the powder if a capsule is opened?

Yes, regulatory and safety information warns against inhaling the powder if a capsule is opened. Inhaling the contents, which contain active enzymes, can cause irritation to the lungs and may lead to respiratory symptoms such as coughing or difficulty breathing.

---

Q: Is it true that Cotazym can affect blood sugar levels in people with diabetes?

Official labeling for pancrelipase products notes that the medication may impact blood sugar levels. Official guidance suggests that individuals with conditions like diabetes may need to monitor their glucose levels while taking this drug.

---

Q: Are there any specific concerns for elderly patients using Cotazym?

While Cotazym is approved for adults, regulatory documents advise that dosing recommendations for elderly patients may differ. This is generally because dose calculation is based on fat intake, and older adults might consume less fat per kilogram of body weight.

---

Q: Is it normal to feel full after eating a small amount when taking Cotazym?

Feeling full after eating a small amount is a potential side effect that has been reported in clinical experience with pancrelipase products. This symptom, if experienced, is generally considered a change to discuss with the prescriber.

---

Q: Can Cotazym cause constipation, and if so, how is that related to the drug?

Constipation is listed as a common side effect of Cotazym in official safety documents. Although the exact reason is not always specified, general guidance on pancreatic enzyme therapy suggests that factors like inappropriate dosing or insufficient hydration while taking the medication can contribute to changes in bowel habits.

---

Q: Can taking Cotazym affect the absorption of other prescription medications?

Official information states that the medicine is not absorbed into the bloodstream, making systemic drug interactions unlikely. However, because Cotazym works directly in the digestive tract, it can locally affect the efficacy or absorption of other orally administered medications that also work in the gut.

---

Q: Does Cotazym contain lactose or other common allergens?

The most critical allergy warning associated with this medicine is known hypersensitivity to porcine (pig) protein, which is the source of the enzymes. While the product monograph lists all components, some pancrelipase products have contained lactose, leading to a general caution for those with lactose intolerance.

---

Q: Are there different strengths of Cotazym capsules, and how are they designated (e.g., ECS 8, ECS 20)?

Yes, official labeling confirms that Cotazym capsules are available in different strengths, which is typical for pancreatic enzyme replacement therapies. These are designated on the label using abbreviations that indicate the units of lipase activity, such as COTAZYM® ECS 8 and COTAZYM® ECS 20.

---

Q: Does a person need a special diet while taking Cotazym?

Official patient guidance explains that the enzyme dose is individualized and calculated based on a patient's diet, specifically the amount of fat consumed. Therefore, patients are often advised to adhere to a special diet recommended by their healthcare provider to achieve the best therapeutic results.

---

Q: What are the potential signs of gout that someone taking Cotazym should watch for?

Because the drug contains purines, which can increase uric acid levels, official safety information advises watching for signs of gout or hyperuricemia. These signs can include joint pain or swelling, muscle aches, or stiffness, particularly in the big toe.

---

Q: Is it safe to use Cotazym if a person has a history of intestinal blockage?

Official product monographs advise caution when administering Cotazym to patients who have a pre-existing history of intestinal blockage, stricture, or scarring of the bowel wall (fibrosing colonopathy). This is particularly relevant due to the rare, serious bowel disorder warning associated with high-dose, long-term use.

---

Q: Are there any official restrictions on taking Cotazym with certain types of liquids, like milk?

Official administration instructions advise against mixing the contents of the capsule directly with certain alkaline foods or liquids, such as milk, breast milk, or infant formula. Alkaline substances can potentially reduce the effectiveness of the enzymes by damaging their enteric coating.

---

Q: Does taking Cotazym cause a sore throat or cough?

Cough and sore throat are symptoms that have been reported as possible side effects associated with the use of pancrelipase products. Regulatory warnings also note that if the capsule or its contents are chewed or held in the mouth, the enzymes can cause local irritation to the mouth and throat.

Storage Conditions and Requirements

Cotazym must be stored in a dry place at room temperature, with the labeled requirement specifying storage below 25 C. The enzyme product must be kept in its original container and must be closed tightly between uses to ensure protection from moisture and prevent degradation. Regulatory instructions state that the medicine should not be refrigerated or frozen and must be kept out of the reach of children.

Disposal Instructions

Unused or expired Cotazym should be handled according to official guidance. Regulatory documents instruct users to ask a pharmacist or healthcare professional for directions on how to dispose of the medication safely. The product must not be disposed of in wastewater (such as flushing down a toilet or sink) or thrown into regular household garbage.